Rafivirumab  (Synonyms: CR57)

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails^[1][2][3].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Human

Rafivirumab shows neutralization effect against series of RABV isolates^[2].
Rafivirumab binds to antigenic site I of the RABV glycoprotein^[3].
Rafivirumab fully neutralizs the wild type ERA₄₃₉ and N336D R346K with EC₅₀ ranging between 3 and 5 pg/mL^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rafivirumab (3-12 μg/kg,i.m.) together with CR4098 increases survival in syrian hamsters infected with bat rabies viruses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

944548-37-2

Liquid

Colorless to light yellow

[Rafivirumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• [1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45.  [Content Brief]

  [2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48.  [Content Brief]

  [3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403.  [Content Brief]